Life Science and Technology

Shanghai Laifu Life Science and Technology Co., Ltd. is a clinical-stage biopharmaceutical company with comprehensive capabilities in the discovery, research and development, process development, and production of innovative cell and gene therapies (CGT). The company was established on December 26, 2013. The firm focuses on addressing severe diseases with limited treatment options, with a strategic focus on cell therapy, gene therapy, and tissue repair and regeneration.

The company's leadership team includes Bowan Chen as Chairman & CEO and Zezu Wu, known as the 'father of hematopoietic stem cells in China,' as the Chief Scientist. Other key figures include Xinxiao Zheng as Chief Scientific Medical Officer and Jian Dong as Chief Scientific Officer. The company's development includes securing A-round financing in June 2016 and receiving AABB accreditation for its subsidiary, Shanghai Laifu Medical Technology Co., Ltd., in May 2019 for both immune and stem cells.

Laifu's drug pipeline includes treatments for conditions such as idiopathic pulmonary fibrosis (IPF), for which it has received clinical trial approval for its human umbilical cord mesenchymal stem cell injection. The company has also developed a lentiviral stable transfection technology platform, which forms the basis for its MSC, CAR-T, and CAR NK gene therapy drug pipelines targeting solid tumors and other diseases. Their business model integrates the entire process from research to commercialization, including cell storage, preparation, and quality inspection, positioning itself to capitalize on the growing field of regenerative medicine.

Keywords: cell and gene therapy, biopharmaceutical, clinical-stage, stem cell therapy, regenerative medicine, oncology, immunotherapy, tissue repair, drug development, idiopathic pulmonary fibrosis, CAR-T, mesenchymal stem cells, clinical trials, AABB accredited, life sciences, CGT, biologics, lentiviral platform, drug discovery, process development